Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair loss diagnosed as chronic Telogen Effluvium and male pattern baldness, treated with finasteride and minoxidil, later switching to dutasteride due to side effects but with limited success. The user plans to return to finasteride due to side effects from dutasteride, while others suggest maintaining consistent treatment and considering additional options like oral minoxidil and lifestyle changes.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user seeks input from medical professionals and scientists on these treatments.

Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.

The conversation humorously discusses an extensive and exaggerated hair loss treatment regimen, including finasteride, dutasteride, minoxidil, pyrilutamide, RU58841, and various other therapies. Despite the numerous treatments, the effectiveness is questioned, and the user humorously considers adding more minoxidil.

The conversation is about hair regrowth progress using topical finasteride 0.1%, minoxidil 10%, ketoconazole shampoo, and weekly microneedling. The user plans to continue the treatment for another year to assess its effectiveness.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.

A user suggests that deeper microneedling with Verteporfin injections might help regrow hair in areas with scar tissue, alongside a DHT blocker. Another user explains that hair loss might be due to reduced Wnt/β-Catenin signaling and suggests that treatments like Minoxidil, Finasteride, and microneedling could potentially reverse it.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation is about the effectiveness of Anagain, Capixyl, Procapil, and Redensyl for hair loss, and whether anyone has experience using these ingredients, sometimes in combination with Minoxidil.

A 32-year-old man has been treating his hair loss with daily oral finasteride (1.25g), twice-daily topical minoxidil, weekly ketoconazole 2% shampoo, and weekly microneedling for almost three months, with no side effects from finasteride. He started with a Hamilton Norwood scale rating of 5 and has seen improvement without experiencing pain by using a 0.8mm needle length for microneedling.

The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

This conversation was about a user's progress pictures from using minoxidil and microneedling to treat hair loss. Other users suggested finasteride as an additional treatment, while cautioning that the drug could have permanent side effects.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

Microneedling depth should be customized based on hair type and scalp area, with many users finding 0.5-0.6mm effective for miniaturized hairs to avoid damage. Users report varying pain levels and results, with some preferring shorter needle lengths and others using longer ones like 1.75mm for scalp health and density improvement.

Finasteride improved mental health and reduced hair loss concerns for the original poster. Other users suggested using minoxidil and derma-rolling for better results.

Exosomes are being considered for hair regrowth, with some users reporting initial improvement. One user moved on to using dutasteride and oral minoxidil with positive results.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

The conversation discusses the potential effectiveness of hair loss treatments, with some companies claiming to have a cure by 2019-2025. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

The user is experiencing hair thinning despite using finasteride and minoxidil with added tretinoin, and is considering switching to dutasteride. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.

The user is seeking advice on hair loss treatment after three months on finasteride, having stopped minoxidil due to a rash, and is now using nanoxidil. Suggestions include switching to oral minoxidil, adding dutasteride, and incorporating microneedling for better results.

The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.